Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regeneron Pharmaceutical (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,291,036
  • Shares Outstanding, K 107,150
  • Annual Sales, $ 4,860 M
  • Annual Income, $ 895,520 K
  • 36-Month Beta 1.56
  • Price/Sales 8.52
  • Price/Cash Flow 38.46
  • Price/Book 6.84

Price Performance

See More
Period Period Low Period High Performance
1-Month
381.64 +2.61%
on 11/16/17
444.99 -12.00%
on 10/18/17
-50.97 (-11.52%)
since 10/17/17
3-Month
381.64 +2.61%
on 11/16/17
505.49 -22.53%
on 09/01/17
-72.43 (-15.61%)
since 08/17/17
52-Week
340.09 +15.14%
on 01/26/17
543.55 -27.96%
on 06/22/17
-12.97 (-3.21%)
since 11/17/16

Most Recent Stories

More News
Regeneron Announces Upcoming Investor Conference Presentation

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast a management presentation at the 29th Annual Piper Jaffray Healthcare Conference at 4:00 p.m. ET on Tuesday, November 28, 2017.

REGN : 391.59 (-0.79%)
Biotech on the Brink!

This post Biotech on the Brink! appeared first on Daily Reckoning . It’s do-or-die for biotech stocks. Today, Greg Guenthner sets the tone for the final weeks of 2017… The post Biotech on the...

BLUE : 163.20 (+1.90%)
IBB : 311.21 (+0.13%)
GILD : 72.44 (+0.04%)
REGN : 391.59 (-0.79%)
AMGN : 170.00 (-0.45%)
XBI : 81.43 (unch)
Inovio (INO) Q3 Loss Wider Than Expected, Revenues Miss

Inovio (INO) reports wider-than-expected loss in Q3. Revenues decline year over year due to lower grants received from DARPA for development of Ebola vaccine.

AZN : 33.46 (-0.18%)
INO : 4.72 (+1.72%)
RHHBY : 29.1000 (+0.71%)
REGN : 391.59 (-0.79%)
Ophthotech (OPHT) Q3 Earnings & Sales Beat, Zimura in Focus

Ophthotech (OPHT) reported better-than-expected third-quarter earnings and sales. The company continues to advance Zimura in several indications.

OPHT : 3.35 (+4.69%)
NVS : 83.98 (+1.16%)
RHHBY : 29.1000 (+0.71%)
REGN : 391.59 (-0.79%)
Biotech Stock Roundup: Regeneron Delivers Strong Q3 Results, Cellectis Clinical Hold Lifted

While focus remained on Regeneron's (REGN) Q3 earnings, Dicerna was also in the news related to its collaboration agreement with Boehringer Ingelheim.

DRNA : 9.54 (+0.63%)
KERX : 4.79 (-1.64%)
VRTX : 147.41 (-0.36%)
DVAX : 18.25 (-1.08%)
GILD : 72.44 (+0.04%)
REGN : 391.59 (-0.79%)
CLLS : 23.74 (-1.12%)
Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up

Regeneron reported impressive results in the third quarter driven by strong performance of Eylea.

BAYRY : 31.7900 (-0.05%)
EXEL : 26.38 (+2.13%)
REGN : 391.59 (-0.79%)
SNY : 44.54 (-0.25%)
Regeneron (REGN) Q3 Earnings Beat Estimates

Regeneron (REGN) beats both earnings and sales estimates in the third quarter driven by an increase in Eylea sales.

REGN : 391.59 (-0.79%)
Regeneron Reports Third Quarter 2017 Financial and Operating Results

-- Third quarter 2017 EYLEA® (aflibercept) Injection U.S. net sales increased 12% to $953 million versus third quarter 2016

REGN : 391.59 (-0.79%)
REGENERON PHARMACEUTICALS INC to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 8, 2017 / REGENERON PHARMACEUTICALS INC (NASDAQ: REGN) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 8:30 AM...

REGN : 391.59 (-0.79%)
How to Survive a Biotech Blowup

This post How to Survive a Biotech Blowup appeared first on Daily Reckoning . Big biotech stocks were primed and ready to rip higher at the beginning of the fourth quarter. But, the market threw a...

CELG : 104.10 (+0.73%)
IBB : 311.21 (+0.13%)
GILD : 72.44 (+0.04%)
REGN : 391.59 (-0.79%)
AMGN : 170.00 (-0.45%)
XBI : 81.43 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM....

See More

Key Turning Points

2nd Resistance Point 398.66
1st Resistance Point 395.13
Last Price 391.59
1st Support Level 389.29
2nd Support Level 386.98

See More

52-Week High 543.55
Fibonacci 61.8% 465.83
Fibonacci 50% 441.82
Fibonacci 38.2% 417.81
Last Price 391.59
52-Week Low 340.09

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart